Multiple myeloma primarily affects plasma cells. These plasma cells are derived from B-lymphocyte white blood cells, which are involved in producing antibodies. This disease is characterized by the excessive and abnormal growth of plasma cells, leading to various health problems. Patients with multiple myeloma may experience symptoms such as bone pain, fatigue, frequent infections, and anemia due to the overproduction of these cells. These abnormal cells also produce a specific type of antibody called monoclonal protein (M-protein), which can be identified in the blood or urine and is often used to diagnose and monitor the disease. Treatment for multiple myeloma typically involves a combination of chemotherapy, targeted therapy, and sometimes stem cell transplant. The disease is generally considered manageable but incurable, with treatment focused on controlling symptoms and prolonging survival. Advances in medical research continue to improve the outlook for patients with this complex condition.